A study suggests that anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor is more effective in treating triple-negative breast cancer [11]. This evidence concerns the gene EGFR and triple-negative breast carcinoma.